Article

CIBA Vision to rebrand silicone hydrogel contact lenses

CIBA Vision has announced that Air Optix will be the global brand name for new products and product improvements to CIBA Vision's silicone hydrogel contact lenses in all markets worldwide.

Duluth, GA-CIBA Vision has announced that Air Optix will be the global brand name for new products and product improvements to CIBA Vision's silicone hydrogel contact lenses in all markets worldwide.

According to the company, having one global brand name will allow CIBA Vision to simplify its business operations and enhance customer satisfaction. It also will allow improved speed to market with future product innovations.

This spring will see the U.S. launch of its silicone hydrogel contact lens (Air Optix for Astigmatism). The lens has an 8 | 4 lens design that features a wide optic zone for optimal visual acuity and helps ensure that the lens fitting characteristics and axis orientation are consistent from patient to patient.

The lenses are made of lotrafilcon B and have a Dk/t of 108 @ –3.00 D. Launch parameters are from plano to –6.00 D in 0.25-D steps, with cylinder powers of –0.75 and –1.25 D and axes around-the-clock in 10° steps. They have a diameter of 14.5 mm, a base curve of 8.7 mm, and feature a blue handling tint. The lenses are approved for daily wear, up to 6 nights of extended wear, and are recommended for monthly replacement.

Including a recommended monthly modality for Air Optix products helps encourage higher patient compliance. Research provided by the company shows 56% patient compliance for wearing monthly lenses, an increase of more than twice the compliance rate of 1- to 2-week lenses. As few as 26% of patients wearing 1- to 2-week disposable-type contact lenses are compliant with the recommended replacement schedule.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.